Literature DB >> 36032603

Nipah amidst Covid-19 Pandemic, another Re-Emerging Infectious Disease of Pandemic Potential - a Narrative Review.

Ariyanachi Kaliappan1, Vanangamudi Kaliappan2, Jyothi Tadi Lakshmi3, S Raja3, Shalam Shireen Nikhat3, Meena S Vidya4, Mallamgunta Saranya5, Triveni Sagar6, Kesavulu Dara Chenna6.   

Abstract

Introduction: Nipah virus (NiV) was reported for the first time from the Kampung Sungai Nipah village of Malaysia in 1998. Since then, there have been multiple outbreaks, all of them in South- and South-East Asia. According to the World Health Organization (WHO), up to 75% of Nipah infections were proven to be fatal. Nipah virus belongs to the group of Biosafety Level-4 pathogen associated with high case fatality rate (40-75%). Methodology:According to the PRISMA guidelines for 2020, we searched in four medical databases (PubMed, Google Scholar, EMBASE and Scopus) and selected relevant studies from the past twenty years till November 2021. Review:Nipah virus was first detected in Malaysia's Kampung Sungai Nipah in 1998. By May 1999, the Malaysia Ministry of Health in association with the Centers for Disease Control (CDC) reported a total of 258 cases with a case fatality rate of almost 40%. Nipah in Kozhikode:Experts from the Pune Institute and Bhopal's National Institute of High Security Animal Diseases had collected Bat samples from Pazhoor in Chathamangalam gram panchayat (where a 12-year-old died due to Nipah infection on September 5 carried antibodies of the virus). All Indian outbreaks have seen person-to-person transmission. The virus found in Kerala differed from those two variants in terms of genetic structure. It also differed by 1.96% from the Bangladesh variant. The difference with the Malaysian variant was 8.42%. While PCR is the most sensitive technique for diagnosing active NiV infection, NiV-specific IgM ELISA offers a serological option when PCR is not available. Conclusions:Understanding the fruit bat ecology, NiV illness seasonality, and the transmission risk of various intermediate species requires a One Health approach. The danger of reintroduction into animal or human populations cannot be handled without a thorough understanding of the wildlife reservoir.

Entities:  

Year:  2022        PMID: 36032603      PMCID: PMC9375865          DOI: 10.26574/maedica.2022.17.2.464

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN: 1841-9038


  34 in total

1.  A rapid immune plaque assay for the detection of Hendra and Nipah viruses and anti-virus antibodies.

Authors:  Gary Crameri; Lin-Fa Wang; Christopher Morrissy; John White; Bryan T Eaton
Journal:  J Virol Methods       Date:  2002-01       Impact factor: 2.014

2.  The pandemic potential of Nipah virus.

Authors:  Stephen P Luby
Journal:  Antiviral Res       Date:  2013-07-30       Impact factor: 5.970

3.  Relapsed and late-onset Nipah encephalitis.

Authors:  Chong Tin Tan; Khean Jin Goh; Kum Thong Wong; Sazilah Ahmad Sarji; Kaw Bing Chua; Nee Kong Chew; Paramsothy Murugasu; Yet Lin Loh; Heng Thay Chong; Kay Sin Tan; Tarmizi Thayaparan; Shalini Kumar; Mohd Rani Jusoh
Journal:  Ann Neurol       Date:  2002-06       Impact factor: 10.422

Review 4.  The emergence of Nipah virus, a highly pathogenic paramyxovirus.

Authors:  Michael K Lo; Paul A Rota
Journal:  J Clin Virol       Date:  2008-10-02       Impact factor: 3.168

5.  Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins.

Authors:  Ha V Dang; Robert W Cross; Viktoriya Borisevich; Zachary A Bornholdt; Brandyn R West; Yee-Peng Chan; Chad E Mire; Sofia Cheliout Da Silva; Antony S Dimitrov; Lianying Yan; Moushimi Amaya; Chanakha K Navaratnarajah; Larry Zeitlin; Thomas W Geisbert; Christopher C Broder; David Veesler
Journal:  Nat Struct Mol Biol       Date:  2021-04-29       Impact factor: 15.369

6.  Nipah Virus Sequences from Humans and Bats during Nipah Outbreak, Kerala, India, 2018.

Authors:  Pragya D Yadav; Anita M Shete; G Arun Kumar; Prasad Sarkale; Rima R Sahay; Chandni Radhakrishnan; Rajen Lakra; Prachi Pardeshi; Nivedita Gupta; Raman R Gangakhedkar; V R Rajendran; Rajeev Sadanandan; Devendra T Mourya
Journal:  Emerg Infect Dis       Date:  2019-05       Impact factor: 6.883

7.  A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus.

Authors:  Thomas W Geisbert; Kathryn Bobb; Viktoriya Borisevich; Joan B Geisbert; Krystle N Agans; Robert W Cross; Abhishek N Prasad; Karla A Fenton; Hao Yu; Timothy R Fouts; Christopher C Broder; Antony S Dimitrov
Journal:  NPJ Vaccines       Date:  2021-02-08       Impact factor: 7.344

8.  Risk factors for Nipah virus encephalitis in Bangladesh.

Authors:  Joel M Montgomery; Mohamed J Hossain; E Gurley; Gurley D S Carroll; A Croisier; E Bertherat; N Asgari; P Formenty; N Keeler; J Comer; M R Bell; K Akram; A R Molla; K Zaman; Mohamed R Islam; K Wagoner; J N Mills; P E Rollin; T G Ksiazek; R F Breiman
Journal:  Emerg Infect Dis       Date:  2008-10       Impact factor: 6.883

Review 9.  Nipah Outbreak: Is it the beginning of another pandemic in the era of COVID-19 and Zika.

Authors:  Vikram Thakur; Pryanka Thakur; Radha Kanta Ratho
Journal:  Brain Behav Immun       Date:  2021-09-22       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.